Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05455697 |
| Title | Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | University of Washington |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |